Akebia Therapeutics Inc (NASDAQ:AKBA)

0.455
BATS BZX Real-Time Price
As of 1:36pm ET
 -0.001 / -0.22%
Today’s Change
0.30
Today|||52-Week Range
3.63
-79.87%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$71.4M

Company Description

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Contact Information

Akebia Therapeutics, Inc.
245 First Street
Cambridge Massachusetts 02142
P:(617) 871-2098
Investor Relations:

Employees

Shareholders

Individual stakeholders7.46%
Mutual fund holders26.64%
Other institutional19.28%

Top Executives

John P. ButlerPresident, Chief Executive Officer & Director
Michel DahanChief Operating Officer & Senior Vice President
David A. SpellmanChief Financial Officer, Treasurer & Senior VP
Steven K. BurkeChief Medical Officer & Senior Vice President
Michael RabinowitzVice President-Research